Simulations Plus (NASDAQ:SLP) Updates FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.070-1.200 for the period. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $91.8 million. Simulations Plus also updated its FY25 guidance to $1.07 to $1.20 EPS.

Simulations Plus Price Performance

SLP stock traded down $0.28 during mid-day trading on Friday, reaching $30.68. 276,743 shares of the company traded hands, compared to its average volume of 130,076. Simulations Plus has a 52-week low of $29.37 and a 52-week high of $51.22. The company has a market capitalization of $613.91 million, a P/E ratio of 63.92 and a beta of 0.69. The company has a fifty day moving average price of $33.08 and a 200-day moving average price of $40.63.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Wednesday, October 23rd. The technology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm had revenue of $18.70 million during the quarter, compared to the consensus estimate of $19.73 million. During the same period last year, the firm earned $0.18 EPS. The business’s quarterly revenue was up 19.9% compared to the same quarter last year. As a group, analysts forecast that Simulations Plus will post 0.54 EPS for the current year.

Wall Street Analysts Forecast Growth

SLP has been the topic of several research analyst reports. BTIG Research decreased their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a research report on Thursday. JMP Securities started coverage on shares of Simulations Plus in a report on Tuesday, July 16th. They issued a “market perform” rating on the stock. Craig Hallum reaffirmed a “buy” rating and set a $56.00 price objective on shares of Simulations Plus in a report on Wednesday, July 3rd. William Blair reissued an “outperform” rating on shares of Simulations Plus in a research note on Thursday. Finally, KeyCorp started coverage on Simulations Plus in a research note on Monday, July 29th. They set an “overweight” rating and a $47.00 price target for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Simulations Plus has an average rating of “Moderate Buy” and a consensus target price of $54.50.

Insider Activity at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $39.63, for a total transaction of $792,600.00. Following the completion of the sale, the director now directly owns 3,521,592 shares in the company, valued at $139,560,690.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last 90 days, insiders have sold 60,750 shares of company stock valued at $2,145,055. Insiders own 20.90% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.